INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP filed a securities class action against Park Ha Biological Technology (NASDAQ: BYAH), alleging the company’s shares were involved in a social-media-driven pump-and-dump and market-manipulation scheme following its IPO. The complaint says BYAH surged from its $4.00 IPO price to $41.49 on July 7, 2025, without material corporate developments, before subsequently collapsing. Investors who acquired shares during the class period have until September 28, 2026, to seek appointment as lead plaintiff.

Analysis

This is primarily a liquidity and governance-risk signal rather than a standalone fundamental catalyst. For BYAH, the relevant transmission mechanism is likely a further contraction in the addressable institutional buyer base: compliance screens, broker restrictions, and limited borrow can reduce two-way liquidity and widen spreads well before any adjudication. The lead-plaintiff deadline is not a merits determination, so the near-term legal headline risk is asymmetric but not independently investable without verified disclosure, trading, and shareholder-concentration data.

The second-order risk is financing optionality. If the company requires equity capital over the next 6-18 months, a depressed and volatile share price raises dilution, warrant-reset, and reverse-split risk; those outcomes can matter more to residual equity value than eventual class-action damages. Conversely, the consensus may overread a plaintiff-law-firm announcement: these releases frequently follow large drawdowns and do not establish liability. A sharp rebound remains possible if promotional-flow selling has already exhausted, particularly in a thin float where short positioning can be structurally difficult.

For the next days to weeks, monitor exchange compliance notices, Form 6-K/20-F disclosures, auditor changes, related-party transactions, insider/large-holder sales, and daily turnover relative to free float. Over 1-3 months, the key falsifier of the bearish governance thesis would be independently verifiable operating disclosures, credible institutional financing without deeply discounted warrants, and sustained trading liquidity at materially tighter spreads. Absent those, any apparent price strength should be treated as technical rather than a durable rerating.

Key Decisions for Investors

• Do not initiate a directional BYAH short solely on this release. Treat as a restricted/watch-list name until borrow availability, borrow cost, float, and locate reliability are confirmed; forced buy-ins and gap risk can overwhelm a correct thesis.
• If existing long exposure is unavoidable, reduce to a de minimis event-risk position before the September 28 lead-plaintiff deadline and avoid averaging down. Reassess only after reviewing primary-source company filings and exchange-compliance status.
• Set a BYAH alert for any discounted equity financing, warrant issuance/reset, reverse-split proposal, auditor resignation, or delisting notice over the next 1-3 months; any of these would validate a lower-equity-value path and create a better-defined short/watch opportunity if borrow is available.
• Avoid using broad biotech or IPO ETFs as a hedge: BYAH-specific governance and microcap liquidity risk has negligible read-through to XBI, IBB, or Renaissance IPO ETF holdings.